Abstract
A phospholipid drug delivery nanosystem with particle size up to 30 nm elaborated at the Orekhovich Institute of Biomedical Chemistry (Russian Academy of Medical Sciences) has been used earlier for incorporation of doxorubicin (Doxolip). This system demonstrated higher antitumor effect in vivo as compared with free doxorubicin. In this study the effect of this nanosystem containing doxorubicin on HepG2 cell proteome has been investigated. Cells were incubated in a medium containing phospholipid nanoparticles (0.5 μg/mL doxorubicin, 10 μg/mL phosphatidylcholine). After incubation for 48 h their survival represented 10% as compared with untreated cells. Cell proteins were analyzed by quantitative two-dimensional gel electrophoresis followed by identification of differentially expressed proteins with MALDI-TOF mass spectrometry. The phospholipid transport nanosystem itself insignificantly influenced the cell proteome thus confirming previous data on its safety. Doxorubicin, as both free substance and Doxolip (i.e., included into phospholipid nanoparticles) induced changes in expression of 28 proteins. Among these proteins only four of them demonstrated different in response to the effect of the free drug substance and Doxolip. Doxolip exhibited a more pronounced effect on expression of certain proteins; the latter indirectly implies increased penetration of the drug substance (included into nanoparticles) into the tumor cells. Increased antitumor activity of doxorubicin included into phospholipid nanoparticles may be associated with more active increase of specific protein expression.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dusinska, M., Nanomedicine, 2009, vol. 4, pp. 605–607.
Archakov, A.I., Biomed. Khim., 2010, vol. 56, pp. 7–25.
Govorun, V.M. and Archakov, A.I., Biochemistry (Moscow), 2002, vol. 67, pp. 1341–1359.
Hong, M.L., Jiang, N., Gopinath, S., and Chew, F.T., Clin. Exp. Pharmacol. Physiol., 2006, vol. 33, pp. 563–568.
Moshkovskii, S.A., Sokolova, E.E., Brattseva, E.V., Karpova, M.A., Pyatnitskiy, M.A., Kubanova, A.A., and Archakov, A.I., Proteomics Clin. Appl., 2011, vol. 5, no. 78, pp. 432–439.
Agrawal, G.K., Timperio, A.M., Zolla, L., Bansal, V., Shukla, R., and Rakwal, R., J. Proteomics, 2013, Apr. 22. pii: S1874–3919 [Epub ahead of print].
Johnson, C.J., Zhukovsky, N., Cass, A.E., and Nagy, J.M., Proteomics, 2008, vol. 8, no. 4, pp. 715–730.
Rafati, H. and Mirzajani, F., Pharmazie, 2011, vol. 66, no. 1, pp. 31–36.
Archakov, A.I., Guseva, M.K., Uchaikin, V.F., Ipatova, O.M., Tikhonova, E.G., Medvedeva, N.V., Lisitsa, A.V., Prozoroskii, V.N., Strekalova, O.S., and Shironin, A.V., Rus Patent no. 2391966, Byul. Izobret., 2010, no. 17.
Ipatova, O.M., Prozorovskiy, V.N., Medvedeva, N.V., Shironin, A.V., Strekalova, O.S., Ivanova, N.D., Torkhovskaya, T.I., and Archakov, A.I., Eur. Congress for Drug Discovery (MipTec), 2010, Basel, Abstr. 80.
Archkov, A.I., Ipatova, O.M., Medvedeva, N.V., Prozoroskii, V.N., Torkhovskaya, T.I., Tikhonova, E.G., Zykova, M.G., and Voskresenskaya, A.A., Rus. Patent no. 2411935, Byul. Izobret., 2011, no. 5.
Zykova, M.A., Ipatova, O.M., Prozorovskii, V.N., Medvedeva, N.V., Voskresenskaya, A.A., Zakharova, T.S., and Torkhovskaya, T.I., Biomed. Khim., 2011, vol. 57, pp. 174–179.
Zykova, M.A., Medvedeva, N.V., Torkhovskaya, T.I., Tikhonova, E.G., Prozorovskii, V.N., Zakharova, T.S., and Ipatova, O.M., Exp. Oncol., 2012, vol. 34, no. 4, pp. 323–326.
Hammer, E., Bien, S., Salazar, M.G., Steil, L., Scharf, C., Hildebrandt, P., Schroeder, H.W., Kroemer, H.K., Vösker, U., and Ritter, C.A., Proteomics, 2010, vol. 10, pp. 99–114.
Gorg, A., Postel, W., and Gunther, S., Electrophoresis, 1985, vol. 6, pp. 599–604.
O’Farrell, P., J. Biol. Chem., 1975, vol. 250, pp. 4007–4021.
Mortz, E., Krogh, T.N., Vorum, H., and Görg, A., Proteomics, 2001, vol. 1, pp. 1359–1363.
Van Summeren, A., Renes, J., Bouwman, F.G., Noben, J.P., van Delft, J.H., Kleinjans, J.C., and Mariman, E.C., Toxicol. Sci., 2011, vol. 129, no. 1, pp. 109–122.
Havlis, J., Thomas, H., Sebela, M., and Shevchenko, A., Anal. Chem., 2003, vol. 75, no. 6, pp. 1300–1306.
Bien, S., Ritter, C.A., Kranz, M., Scharf, C., Steil, L., Hummel, M., Vösker, U., Cascorbi, I., and Kroemer, H.K., J. Clin. Pharmacol. Ther., 2004, vol. 42, no. 11, pp. 640–641.
Wu, Z., Jia, X., de la Cruz, L., Su, X.C., Marzolf, B., Troisch, P., Zak, D., Hamilton, A., Whittle, B., Yu, D., Sheahan, D., Bertram, E., Aderem, A., Otting, G., Goodnow, C.C., and Hoyne, G.F., Immunity, 2008, vol. 29, pp. 863–875.
Robertson, N., Potter, C., and Harris, A.L., Cancer Research, 2004, vol. 64, pp. 6160–6165.
Li, X., Ding, L., Xu, Y., Wang, Y., and Ping, Q., Int. J. Pharm., 2009, vol. 373, pp. 116–123.
Li, L., Gong, H., Yu, H., Liu, X., Liu, Q., Yan, G., Zhang, Y., Lu, H., Zou, Y., and Yang, P., J. Cell Biochem., 2012, vol. 113, pp. 3788–3796.
Honoré, B., Buus, S., and Claësson, M.H., Proteome Sci., 2008, vol. 6, p. 18.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © K.G. Kuznetzova, E.V. Kazlas, T.I. Torkhovskaya, P.A. Karalkin, I.V. Vachrushev, T.S. Zakharova, M.A. Sanzhakov, S.A. Moshkovskii, O.M. Ipatova, 2014, published in Biomeditsinskaya Khimiya.
Rights and permissions
About this article
Cite this article
Kuznetzova, K.G., Kazlas, E.V., Torkhovskaya, T.I. et al. The effect of doxorubicin incorporated into a phospholipid delivery nanosystem on HepG2 cells proteome. Biochem. Moscow Suppl. Ser. B 8, 77–83 (2014). https://doi.org/10.1134/S1990750814010090
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1990750814010090